@article{Wade:2026:10.1007/s00467-026-07166-0,
author = {Wade, J and Thomas, DC and Pickering, MC and Medjeral-Thomas, NR},
doi = {10.1007/s00467-026-07166-0},
journal = {Pediatr Nephrol},
pages = {3231--3246},
title = {Complement and kidney diseases: unlocking the opportunity of targeted treatments for glomerular diseases, including IgA nephropathy.},
url = {http://dx.doi.org/10.1007/s00467-026-07166-0},
volume = {41},
year = {2026}
}

Download

TY  - JOUR
AB  - The imminent availability of multiple therapeutic complement inhibitors, which target different complement pathway components, could revolutionise treatment for a broad range of kidney diseases. However, the complexity of complement activity within and between kidney diseases, for which IgA nephropathy is an illustrative example, and the possible adverse effects of complement inhibition mean robust patient selection and stratification to appropriately targeted inhibitors will be needed to maximise this therapeutic opportunity. Despite promising candidates, novel biomarkers that stratify patients to targeted complement inhibition have not yet been validated for clinical practice.
AU  - Wade,J
AU  - Thomas,DC
AU  - Pickering,MC
AU  - Medjeral-Thomas,NR
DO  - 10.1007/s00467-026-07166-0
EP  - 3246
PY  - 2026///
SP  - 3231
TI  - Complement and kidney diseases: unlocking the opportunity of targeted treatments for glomerular diseases, including IgA nephropathy.
T2  - Pediatr Nephrol
UR  - http://dx.doi.org/10.1007/s00467-026-07166-0
UR  - https://www.ncbi.nlm.nih.gov/pubmed/41714421
VL  - 41
ER  - 

Download